Gene therapy preparations manufacturing · New Jersey

Novartis Pharmaceuticals

Morris Plains, NJ · ~454 workers · 9 years of OSHA Injury Tracking Application data.

B
Good Safety Record
2.0
Avg TCR
3.3
Industry avg
0
Fatalities
Subscribe to safety-record updates (RSS)

The verdict

Novartis Pharmaceuticals runs at 60% of its industry's injury rate - safer than the typical Gene therapy preparations manufacturing workplace, earning a grade B.

Novartis Pharmaceuticals: 2.0 TCR = 60% of Gene therapy preparations manufacturing BLS 3.3 · 9y Form 300A (see methodology below)

Novartis Pharmaceuticals safety composite

Novartis Pharmaceuticals scores strongest on fatalities (safer than 50% of same-industry peers) and weakest on dart rate (safer than 23%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).

F

31/100

Percentile-weighted across 3 of 3 measures

Total Case Rate (TCR)
F 1.99 per 100 workers

Safer than 27% of industry peers

DART rate
F 1.46 per 100 workers

Safer than 23% of industry peers

Fatalities
D 0

Safer than 50% of industry peers

Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).

Rising injury rate

Novartis Pharmaceuticals: 0.0 → 2.4 TCR

Peak year 2021 @ 4.3 TCR · DART/TCR 0.73× in 2024

Novartis Pharmaceuticals's TCR rose 2.4 from 0.0 in 2016 to 2.4 in 2024. Peak filing year was 2021 at 4.3 TCR. In 2024, DART was 0.73× this establishment's average TCR (severity share of cases).

OSHA ITA Form 300A scorecard

Establishment book 325414 · Morris Plains, NJ AT/BELOW-IND · MID

Grade B · TCR 2.0 · 60% of ind

  • DART 1.5 DART
  • RANK #9/9
  • PHOTO Shire: Alewife
  • BOOK 9y book
  • INJ 49 inj
  • SIZE ~454 FTE

Nearest TCR peer: Shire: Alewife (0.0 TCR gap)

Read with this employer → · Industry book → · New Jersey employers → · Look up another →

Novartis Pharmaceuticals in the TCR neighbourhood

Average Total Case Rate among this establishment and nearest same-industry peers

TCR

What this shows Novartis Pharmaceuticals averages 2.0 TCR (60% of the Gene therapy preparations manufacturing BLS benchmark).

Source U.S. Department of Labor, OSHA Injury Tracking Application (Form 300A) As of 2026-08-25

Novartis Pharmaceuticals TCR series: 2016=0 · 2017=1.2 · 2018=0.9 · 2019=1.6 · 2020=1.4 · 2021=4.3 · 2022=3.4 · 2023=2.9 · 2024=2.4 · BLS 3.3

Where Novartis Pharmaceuticals falls in its industry

234 Gene therapy preparations manu establishments

Safer than 27% of graded establishments in this industry, whose median TCR is 1.2.

More dangerous than peersSafer than peers

Narrower to New Jersey alone (the establishments it most directly competes with for workers and contracts): ranked #9 safest of 9 Gene therapy preparations manu employers in New Jersey.

Novartis Pharmaceuticals (454 employees, TCR 2.0) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2 2×2 strategic matrix plotting 30 entities by Average employees (X) and Total Case Rate (Y), with a crosshair dividing the plot into four quadrants. Larger & higher-riskSmaller & higher-riskLarger & saferSmaller & safer than peers 05001,0001,5002,000 0246 Average employees Total Case Rate Novartis Pharmaceuticals
Novartis Pharmaceuticals (454 employees, TCR 2.0) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2

Novartis Pharmaceuticals has more employees than the Gene therapy preparations manufacturing median and a higher injury rate than the industry's median TCR of 1.2. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.

Year-by-Year Safety Data

Year TCR DART Injuries Illnesses Fatalities
2024 2.4 1.5 9 1 0
2023 2.9 2.9 6 5 0
2022 3.4 3.4 3 8 0
2021 4.3 3.8 10 8 0
2020 1.4 1.0 6 4 0
2019 1.6 1.1 7 4 0
2018 0.9 0.5 5 0 0
2017 1.2 0.4 3 0 0
2016 0.0 0.0 0 0 0

OSHA ITA peer cross-reference

Establishment peer ledger

325414 · NJ · Morris Plains

234 Gene therapy preparations manufacturing employers nationwide with a credible TCR · 11,201 rated employers in New Jersey with headcount on file · 35 employers in Morris Plains, NJ · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.

Rel Establishment Metric
NAICS-TCR Shire: Alewife 2.0 TCR
NAICS-TCR Smith & Nephew Columbia MD 2.0 TCR
NAICS-TCR Elanco Maine Winslow 2.0 TCR
NAICS-TCR Shire - Milford MA 2.0 TCR
STATE-SIZE Cranbury 1 454 FTE
STATE-SIZE USA - Iselin, S Wood 454 FTE
STATE-SIZE 1800 Bishops Gate 454 FTE
STATE-SIZE 8807746-WILLIAMS SONOMA-ECDC-NJ 454 FTE
CITY-NEAR Morris Plains HQ - NJ11 544 FTE
CITY-NEAR Honeywell HQ 544 FTE
CITY-NEAR Primary Care Partners 371 FTE
CITY-NEAR PMT Honeywell Morris Plains 319 FTE
NAT-TCR Binghamton 2.0 TCR
NAT-TCR Indianapolis 79th Street 2.0 TCR
NAT-TCR Union Electric Contracting Company Main Office and Temporary Establishments 2.0 TCR
NAT-TCR Antlers Housecall 2.0 TCR
NAT-SIZE 177 Aut - Winston Salem 454 FTE
NAT-SIZE Lennar Southwest Florida 454 FTE
NAT-SIZE Humphrey & Associates 454 FTE
NAT-SIZE Bowers Campus 454 FTE

Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →

Data Source: OSHA Injury Tracking Application (ITA), mandatory establishment-level injury/illness reports. Grades compare employer Total Case Rate (TCR) to BLS IIF industry benchmarks. Data covers years reported by this establishment: 2024, 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016. This is publicly available government data - not a legal determination of workplace conditions.
Data sourced from official public datasets. See our methodology for details.